A review of the animal pharmacology of clobazam: An update
Stuart Fielding, Harbans Lal
Abstract
Stuart Fielding, Harbans Lal
Abstract
Clobazam is a 1, 5-benzodiazepine with significant activity in preclinical tests predictive of potential clinical antianxiety activity. Clinical efficacy equivalent to diazepam has been established with minimal effects on psychomotor performance. Clobazam has also been found to have a broad spectrum of anticonvulsant activity with acceptable toxicity and to be active in suppressing aggressive behavior in rodents. This compound appears to have less of an effect on motor coordination, muscle tone, behavioral depression and hyporeflexia than standard reference compounds in various species as well as little or no apparent effect on memory and learning in animals and humans. The major metabolite, desmethylclobazam, is also an anxiolytic candidate approximately 10 times less potent than diazepam and a potent anticonvulsant with a complete lack of sedation. These compounds represent a new classification of pharmaceutical agents in which antianxiety and anticonvulsant effects can be achieved without sedative or depressive side effects.
OpenAlex reports 9 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Clobazam is a 1, 5-benzodiazepine with significant activity in preclinical tests predictive of potential clinical antianxiety activity. Clinical efficacy equivalent to diazepam has been established with minimal effects on psychomotor performance. Clobazam has also been found to have a broad spectrum of anticonvulsant activity with acceptable toxicity and to be active in suppressing aggressive behavior in rodents. This compound appears to have less of an effect on motor coordination, muscle tone, behavioral depression and hyporeflexia than standard reference compounds in various species as well as little or no apparent effect on memory and learning in animals and humans. The major metabolite, desmethylclobazam, is also an anxiolytic candidate approximately 10 times less potent than diazepam and a potent anticonvulsant with a complete lack of sedation. These compounds represent a new classification of pharmaceutical agents in which antianxiety and anticonvulsant effects can be achieved without sedative or depressive side effects.
Key concepts: Clobazam, Anxiolytic, Hyporeflexia, Pharmacology, Anticonvulsant, Diazepam, Sedative, Sedation